We are are a biotechnology company working to develop an immunotherpay vaccine technology platform based on proprietary antigen optimized pDNA, virus like particle and transdermal delivery device. Our lead product candidate, DermaVir, for the treatment of HIV, is passed Phase II trials. We have shown that our vaccine is as safe as placebo and effective in restarting the immune system to fight the virus.